HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

STAT+: Facing a brutal run, battered vaccine makers still see cause for hope

It's an unusual time to be in the vaccine business. But in the view of those gathered at the BIO conference this week, it's not altogether a bleak one.

By STAT News · Jun 25, 2026 · via STAT News
STAT+: Facing a brutal run, battered vaccine makers still see cause for hope

Image: STAT News

This is an aggregated industry headline. Read the full story at STAT News

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
AstraZeneca has partnered with YMCA of the USA to increase awareness of cancer screening and early detection.…
Jun 25, 2026
Spurned by FDA, Passage Bio finds exit through merger with Remix
The WeekFierceBiotech ↗
Passage Bio, the Philadelphia-based gene therapy outfit that launched a strategic review earlier this year aft…
Jun 25, 2026
Gilead’s Trodelvy Wins Broad Front-Line TNBC Nod, Escalating TROP2 ADC Competition
The WeekBriefing
The FDA approved Trodelvy for first-line triple-negative breast cancer regardless of PD-L1 status, days after …
Jun 25, 2026